ArticleDiscover oncology2026
Comprehensive pan-cancer analysis of RPRD1B as a promising diagnostic and prognostic biomarker.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegulation of nuclear pre-mRNA domain containing 1B (RPRD1B, also known as CREPT), has emerged as a potential factor in cancer development. Despite growing evidence, a comprehensive evaluation of RPRD1B across different cancer types has not been conducted. This study aims to explore its prognostic significance in pan-cancer analysis.
methodsOnline databases and platforms such as The Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), the Human Protein Atlas (HPA), cBioPortal, TIMER2.0, BioGRID, and SangerBox were used to gather data on RPRD1B across various cancers. The pan-cancer patient datasets were analyzed to explore the relationships among RPRD1B expression, genetic alterations, protein interactions, tumor immunity, and clinical features.
resultsThe findings indicate that RPRD1B was upregulated in most tumor types compared to normal tissues, and increased protein levels observed in several cancers. Notably, high RPRD1B expression was associated with the infiltration of immune cells, endothelial cells, and cancer-associated fibroblasts (CAFs), as well as the expression of tumor immune markers in certain cancers. Additionally, elevated RPRD1B expression proved useful for aiding cancer diagnosis and predicting prognosis across multiple cancer types. In vitro studies showed that RPRD1B was upregulated in colon adenocarcinoma (COAD) cell lines, where it promoted cell proliferation and invasion. In vivo experiments further demonstrated that knocking down RPRD1B significantly suppressed tumor growth.
conclusionHigh RPRD1B expression contributes to cancer progression and may function as a key biomarker for the diagnosis and prognosis across various tumor types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.